Mode
Text Size
Log in / Sign up

Hair cortisol concentration correlates with glucocorticoid adequacy and symptoms in adults with adrenal insufficiencyYour Hair Holds a Hidden Record of a Dangerous Hormone Imbalance

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that hair cortisol concentration correlates with glucocorticoid dose and symptoms but requires prospective validation for dose optimization.

This cross-sectional study assessed hair cortisol concentration (HCC) as a marker of glucocorticoid replacement adequacy in 64 adults with adrenal insufficiency (AI) and 64 matched healthy controls. Participants received hydrocortisone treatment, and HCC was measured alongside clinical parameters including fatigue, pain, blood pressure, and anthropometric data.

HCC levels were markedly higher in AI patients (4.3 ng/g) compared to controls (1.75 ng/g; p < 0.01). Primary AI patients exhibited higher HCC (6.5 ng/g) than those with secondary AI (3.8 ng/g; p = 0.037). This difference remained significant even after excluding patients with congenital adrenal hyperplasia (13.8 vs. 3.8 ng/g; p < 0.01).

HCC demonstrated positive correlations with BMI, waist circumference, blood pressure, and hydrocortisone dose, while showing inverse correlations with fatigue, pain, and therapy duration (all p < 0.05). Multivariable analysis identified AI subtype as an independent predictor of HCC; excluding subtype, hydrocortisone dose emerged as the independent predictor. HCC showed excellent discrimination for severe fatigue (AUC 0.906) and pain (AUC 0.898), and good performance for systolic hypertension (AUC 0.837). Undertreated patients had significantly lower HCC (2.1 ng/g) than overtreated patients (14.1 ng/g; p < 0.001).

No safety data regarding adverse events or discontinuations were reported. The primary limitation is the cross-sectional design, which precludes causal inference. Prospective studies are required to determine the utility of HCC in optimizing glucocorticoid dosing. Consequently, HCC should be interpreted as a potential adjunctive tool rather than a standalone diagnostic metric for replacement adequacy.

When Your Body Can't Make Its Own Cortisol

Adrenal insufficiency (AI) is a condition where the adrenal glands — two small glands that sit on top of your kidneys — fail to produce enough cortisol. Cortisol is not just a "stress hormone." It is essential for blood pressure regulation, immune function, blood sugar control, and the basic energy systems that keep you functioning.

People with AI take hydrocortisone tablets every day to replace what their glands cannot produce. Getting the dose right is critical. But unlike insulin in diabetes — where blood sugar gives a real-time readout — there is no equivalent live feed for cortisol. A blood test taken at one moment in time only tells you what cortisol looked like at that exact moment, not whether your body has been adequately supplied over the past weeks or months.

The Limits of the Current Approach

Doctors currently rely on symptoms and occasional blood tests to judge whether a patient's hydrocortisone dose is right. But symptoms are subjective. Fatigue might mean undertreatment — or it might mean stress, poor sleep, or a dozen other things. Overtreated patients often feel fine in the short term, while quietly accumulating damage to blood pressure and metabolism.

But here's the twist: cortisol leaves a trace in your hair as it grows. Hair grows roughly one centimeter per month, and cortisol absorbed into the hair shaft stays there — a built-in timeline of your body's hormone exposure over the past several weeks.

Hair as a Long-Term Hormone Diary

Think of each centimeter of hair as a page in a diary. The outermost segment reflects recent weeks. The segment closer to the scalp reflects the weeks before that. By analyzing the first three centimeters of hair near the scalp, researchers can estimate cortisol exposure over roughly the past three months.

This is called hair cortisol concentration (HCC), and unlike a blood test, it cannot be affected by the stress of a hospital visit or the timing of a morning pill. It reflects what your body actually experienced over an extended period.

Researchers published findings in Frontiers in Medicine after studying 64 adults with hydrocortisone-treated adrenal insufficiency, matched against 64 healthy controls. They measured hair cortisol levels and compared them against symptoms of undertreatment (severe fatigue, significant pain) and signs of overtreatment (high blood pressure, elevated blood sugar, notable weight gain).

They also looked at whether different types of adrenal insufficiency — primary AI (where the adrenal gland itself fails) versus secondary AI (where the brain signal telling the gland to work fails) — produced different patterns.

Numbers That Tell the Difference

The results showed clear separation. Patients who were undertreated had hair cortisol levels averaging 2.1 nanograms per gram of hair. Overtreated patients averaged 14.1 ng/g. That's a more than six-fold difference — a gap large enough to be clinically meaningful.

The test was particularly strong at identifying patients with severe fatigue and pain from undertreatment, with accuracy scores (called AUC) of 0.906 and 0.898 respectively — meaning it correctly identified undertreated patients nearly 90% of the time. It also performed well at detecting signs of overtreatment-related high blood pressure.

This does not mean hair cortisol testing is ready to replace your current monitoring — but the accuracy numbers here are genuinely promising.

A Tool That Could Change Dose Conversations

Right now, if you go to an endocrinologist (a hormone specialist) and say "I feel exhausted all the time," there is often no objective test to confirm whether that exhaustion is from inadequate cortisol replacement. This research suggests that a hair sample collected at a clinic visit could provide a three-month cortisol record that helps answer that question in a way a one-time blood draw simply cannot.

Researchers also found that hair cortisol correlated with BMI, blood pressure, and hydrocortisone dose — suggesting it may reflect a wider picture of how well the body is managing with its current regimen.

A Few Honest Caveats

This was a cross-sectional study of 64 patients — a relatively small sample, observed at one point in time rather than tracked over months. The study cannot prove that adjusting doses based on hair cortisol leads to better long-term outcomes. Hair cortisol can also be affected by cosmetic treatments, some medications, and hair color — all factors that need further study.

The authors recommend prospective studies — where patients are monitored over time and doses are actually adjusted based on hair cortisol readings — to determine whether the test can improve real-world health outcomes. If those studies confirm what this research suggests, hair cortisol testing could eventually become a routine part of managing adrenal insufficiency, giving both patients and doctors a more honest, longer-range view of whether treatment is truly working.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundAchieving physiologic glucocorticoid replacement in adrenal insufficiency (AI) remains challenging, as both under- and over-replacement contribute to morbidity. Hair cortisol concentration (HCC) reflects cumulative cortisol exposure and may provide clinically relevant information beyond single-time-point assessments.MethodsIn this cross-sectional study, 64 adults with hydrocortisone-treated AI and 64 matched healthy controls were evaluated. HCC was measured from the proximal 3-cm hair segment. Clinical, anthropometric, metabolic, and dosing parameters were analyzed. Patients were categorized as undertreated (VAS-fatigue or VAS-pain ≥7) or overtreated (hypertension, hyperglycemia, or ≥5% weight gain). Correlation, ROC, and multivariable regression analyses were performed.ResultsHCC was higher in AI patients than controls (4.3 vs. 1.75 ng/g, p < 0.01). In AI, HCC was higher in primary than in secondary disease (6.5 vs. 3.8 ng/g; p = 0.037); this difference remained significant after excluding patients with congenital adrenal hyperplasia (13.8 vs. 3.8 ng/g; p < 0.01). HCC was positively correlated with BMI, waist circumference, blood pressure, and hydrocortisone dose, and inversely correlated with fatigue, pain, and therapy duration (all p < 0.05). In multivariable analysis, AI subtype remained independently associated with HCC. When the AI subtype was excluded from the model, hydrocortisone dose emerged as an independent predictor. HCC demonstrated excellent discrimination for severe fatigue (AUC 0.906) and pain (AUC 0.898), and good performance for systolic hypertension (AUC 0.837). Undertreated patients had markedly lower HCC than overtreated patients (2.1 vs. 14.1 ng/g, p < 0.001).ConclusionsHCC reflects long-term glucocorticoid exposure in AI and differentiates patterns consistent with both underreplacement and overtreatment. These findings support HCC as a potential adjunctive tool for evaluating replacement adequacy. Prospective studies are needed to determine its role in dose optimization.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.